Want to get in touch?
If you want to learn more about our technology and programs, opportunities to collaborate, or you’re keen to join the AaviGen team, don’t hesitate to reach out to us.
Contact Us
Technology
Gene Therapy for Heart Failure.
We employ Adeno- Associated Viral (AAV) Vectors with precise cardiac tropism, essential elements in pioneering gene therapies for both acquired and genetic disease.
AaviGen’s Next Generation Cardiac AAV Platform.
Creating Vector Libraries
AaviGen leverages cutting-edge experimental and bioinformatic technologies on our hybrid next-cap platform. This platform integrates multiple methodologies to molecularly engineer the capsid, resulting in AAV libraries with a quantitatively and qualitatively high diversity.
Selecting Organ Specific Vectors
Through an iterative systemic selection process in human-relevant model systems, we identify a portfolio of the most suitable organ-specific AAV capsids by consistent bio tracking in organs, tissues and individual cell types. AaviGen’s next-CAP platform intrinsically selects for manufacturability, transduction, and transgene expression.
Tailored to the Target’s Need
AaviGen’s next-CAP platform yields a portfolio or organ specific vectors. By leveraging the unique characteristics of Individual vectors within the portfolio, we optimize lead vector selection to meet specific distribution and expression requirements of the therapeutic target. This optimization leads to an exceptional therapeutic outcome, characterized by high safety, efficacy and manufacturability.
AaviGen’s Next Generation Cardiac AAV Platform.
Creating Vector Libraries
AaviGen leverages cutting-edge experimental and bioinformatic technologies on our hybrid next-cap platform. This platform integrates multiple methodologies to molecularly engineer the capsid, resulting in AAV libraries with a quantitatively and qualitatively high diversity.
Selecting Organ Specific Vectors
Through an iterative systemic selection process in human-relevant model systems, we identify a portfolio of the most suitable organ-specific AAV capsids by consistent bio tracking in organs, tissues and individual cell types. AaviGen’s next-CAP platform intrinsically selects for manufacturability, transduction, and transgene expression.
Tailored to the Target’s Need
AaviGen’s next-CAP platform yields a portfolio or organ specific vectors. By leveraging the unique characteristics of Individual vectors within the portfolio, we optimize lead vector selection to meet specific distribution and expression requirements of the therapeutic target. This optimization leads to an exceptional therapeutic outcome, characterized by high safety, efficacy and manufacturability.
